Our Technologies

%

Dogs Suffer From Osteoarthritis

%

Dogs Suffer from Atopic Dermatitis

%

Cats Suffer from Stomatitis

The application of adipose stem cells as a therapeutic product is the result of years of research and development. In recent years, adipose stem cells (ASCs) have gained notoriety since its initial discovery in 2001 (1). Since then, the ASC has become the most popular adult stem cells due to their safety profile, ease of harvest and ability to differentiate into multiple lineages (2).

VCT has studied the use of adipose tissue in regenerative medicine and is focused on applying scientific findings for use in veterinarian medicine. Most early research was focused on mouse adipose stem cells and recent developments have been centered on adipose stem cells for use in cats and dogs.

A large area of need in veterinary medicine is the treatment of osteoarthritis, which is common in animals as they age. Routine treatment of this ailment is with anti-inflammatory drugs or with surgical procedures. Currently, much of the therapeutic applications have been on autologous ACSs to determine if these cells can treat osteoarthritis (3). The results from these studies are promising and show a great potential to use these cells for a wide array of ailments.

VCT is working on projects aimed at using adipose tissue as a source material to treat osteoarthritis. Our data, along with other publications (4), suggest that adipose tissue may be a reliable source for cells that can be used to treat bone and cartilage conditions as well as other indications (5, 6). The need for an efficient treatment is desired for pets diagnosed with arthritis or other musculoskeletal conditions

A veterinarian scientist, who is well respected in the industry and with an impressive publication history, leads the scientific R&D projects, focusing on generating clinical treatments. The team contains a group of research specialists who all have training in basic research, with a focus on regenerative medicine. The goal is to strive for highly effective products that are backed by research geared towards improving the lives of our beloved pets.

References:

1 | Zuk P., Zhu M., Mizuno H., et al., Tissue Engineering, vol. 7, no. 2, pp 211–228, 2001
2 | Zuk P., ISRN Stem Cells Volume 2013 Article ID 713959
3 | Guercio A., Di Marco P., Casella S., et al, Cell Biology Int, vol 36, (2), pp 189–194, 2012
4 | Lindroos B, Suuronen R, Miettinen S., Stem Cell Rev. Jun 7, (2) pp 269-91, 2011
5 | Lin F., Kidney International vol 82, pp 731–733, 2012
6 | Ha S., Ahn S., Kim S., et al., J Biomed Opt. vol 19(5), 2014

Copyright © 2017 PrimeGen Biotech, LLC

 

 

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images and information, contained on or available through this web site is for general information purposes only. VetCell Therapeutics makes no representation and assumes no responsibility for the accuracy of information contained on or available through this web site, and such information is subject to change without notice.

You are encouraged to confirm any information obtained from or through this web site with other sources, and review all information regarding any medical condition or treatment with your physician.

NEVER DISREGARD PROFESSIONAL MEDICAL ADVICE OR DELAY SEEKING MEDICAL TREATMENT BECAUSE OF SOMETHING YOU HAVE READ ON OR ACCESSED THROUGH ANY WEB SITE.